Expanded Access to Venetoclax

• Conditions: Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma; Acute Myeloid Leukemia (AML); Non-Hodgkin's Lymphoma; Acute Lymphoblastic Leukemia (ALL); Amyloidosis; Plasma Cell Leukemia

• Registration Number: NCT03123029
• Lead Sponsor: AbbVie

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-04-18
• Study First Submitted QC: 2017-04-18
• Study First Posted: 2017-04-21
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-02
• Last Update Posted: 2025-04-04

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• The participant must not be eligible for a venetoclax clinical trial.
• Pediatric participants may be evaluated on a case by case basis.

Exclusion Criteria

Not provided

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified